The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification
Abstract
Immune cells constitute an important element of tumor tissue. Accumulating evidence indicates their clinicopathological significance in predicting prognosis and therapeutic efficacy. Nonetheless, the combinations of immune cells forming the immune microenvironment and their association with histological findings remain largely unknown. Moreover, it is unclear which immune cells or immune microenvironments are the most prognostically significant. Here, we comprehensively analyzed the immune microenvironment and its intratumor heterogeneity in 919 regions of 158 hepatocellular carcinomas (HCCs), and the results were compared with the corresponding histological and prognostic data. Consequently, we classified the immune microenvironment of HCC into three distinct immunosubtypes: Immune‐high, Immune‐mid, and Immune‐low. The Immune‐high subtype was characterized by increased B‐/plasma‐cell and T cell infiltration, and the Immune‐high subtype and B‐cell infiltration were identified as independent positive prognostic factors. Varying degrees of intratumor heterogeneity of the immune microenvironment were observed, some of which reflected the multistep nature of HCC carcinogenesis. However, the predominant pattern of immunosubtype and immune cell infiltration of each tumor was prognostically important. Of note, the Immune‐high subtype was associated with poorly differentiated HCC, cytokeratin 19 (CK19) + , and/or Sal‐like protein 4 (SALL4) + high‐grade HCC, and Hoshida's S1/Boyault's G2 subclasses. Furthermore, patients with high‐grade HCC of the predominant Immune‐high subtype had significantly better prognosis. These results provide a rationale for evaluating the immune microenvironment in addition to the usual histological/molecular classification of HCC. Conclusion : The immune microenvironment of HCC can be classified into three immunosubtypes (Immune‐high, Immune‐mid, and Immune‐low) with additional prognostic impact on histological and molecular classification of HCC. (H epatology 2018)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070 · cited 1×
“HCC is the second- and fifth-leading cause of cancer-related death worldwide and in Japan, respectively.((9)) Studies have shown that increased infiltrations of T, NK, and natural killer T (NKT) cells in HCC are positive prognostic factors,((10-12)) and increased infiltration of Tregs is a negative prognostic factor.”
BackgroundTM4: a free, open-source system for microarray data management and analysis
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003) · BioTechniques · doi:10.2144/03342mt01 · Cited by 4,837
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“Immune cells constitute an important element of tumor tissue, and the amount of immune cell infiltration considerably differs among tumor types and histological subtypes.((1,2)) The recent success of immune checkpoint inhibitors as potential treatments for hepatocellular carcinoma (HCC)((3)) has raised interest in the…”
BackgroundEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Multiplexed ion beam imaging of human breast tumors
Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108
Shen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., et al. (2014) · Nature · doi:10.1038/nature12979 · Cited by 1,048
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976 · cited 7×
“Although recent studies have comprehensively analyzed immune cells in tumor tissues through gene-expression–based and flow cytometric/CyTOF based analyses,((4,5)) comparison of the results with histological features is difficult using these methods.”
BackgroundResultInfluentialBudhu, A., Forgues, M., Ye, Q.-H., Jia, H.-L., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L.-X., Tang, Z.-Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.016 · Cited by 846
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouzé, E., Blanc, J.-F., Laurent, C., Hajji, Y., Azoulay, D., Bioulac-Sage, P., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.014 · Cited by 780
FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D. G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.019 · Cited by 590
Tsujikawa, T., Kumar, S., Borkar, R. N., Azimi, V., Thibault, G., Chang, Y. H., Balter, A., Kawashima, R., Choe, G., Sauer, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.037 · Cited by 568
Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
Matsumoto, M., Baba, A., Yokota, T., Nishikawa, H., Ohkawa, Y., Kayama, H., Kallies, A., Nutt, S. L., Sakaguchi, S., Takeda, K., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.016 · Cited by 556
Zhang, J.-P., Yan, J., Xu, J., Pang, X.-H., Chen, M.-S., Li, L., Wu, C., Li, S.-P., & Zheng, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.033 · Cited by 535
Garnelo, M., Tan, A., Her, Z., Yeong, J., Lim, C. J., Chen, J., Lim, K. H., Weber, A., Chow, P., Chung, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310814 · Cited by 461
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 440
Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration
Wada, Y., Nakashima, O., Kutami, R., Yamamoto, O., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510270214 · Cited by 405
Chew, V., Chen, J., Lee, D., Loh, E., Lee, J., Lim, K. H., Weber, A., Slankamenac, K., Poon, R. T. P., Yang, H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300509 · Cited by 359
Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T‐regulatory cells†‡
Unitt, E., Rushbrook, S. M., Marshall, A., Davies, S., Gibbs, P., Morris, L. S., Coleman, N., & Alexander, G. J. M. (2005) · Hepatology · doi:10.1002/hep.20644 · Cited by 267
Chew, V., Lai, L., Pan, L., Lim, C. J., Li, J., Ong, R., Chua, C., Leong, J. Y., Lim, K. H., Toh, H. C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706559114 · Cited by 248
Shi, J.-Y., Gao, Q., Wang, Z.-C., Zhou, J., Wang, X.-Y., Min, Z.-H., Shi, Y.-H., Shi, G.-M., Ding, Z.-B., Ke, A.-W., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3497 · Cited by 240
Salomao, M., Remotti, H., Vaughan, R., Siegel, A. B., Lefkowitch, J. H., & Moreira, R. K. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.07.005 · Cited by 180
Macrophages induce differentiation of plasma cells through CXCL10/IP-10
Xu, W. D., Joo, H., Clayton, S., Dullaers, M., Herve, M.-C., Blankenship, D., de la Morena, M. T., BALDERAS, R. S., Pïcard, C., Casanova, J., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112142 · Cited by 104
Liu, R., Yuan, W., Zeng, Q., Chan, K., Xiao, C., Zhao, X., Chen, M., Ouyang, F., Chen, D., Zheng, L., et al. (2015) · Hepatology · doi:10.1002/hep.28020 · Cited by 103
Clinicopathological indices to predict hepatocellular carcinoma molecular classification
Tan, P. S., Nakagawa, S., Goossens, N., Venkatesh, A., Huang, T., Ward, S. C., Sun, X., Song, W., Koh, A. P., Canasto‐Chibuque, C., et al. (2015) · Liver International · doi:10.1111/liv.12889 · Cited by 101
Kong, L., Zhu, X., Xu, H., Zhang, J., Lu, L., Wang, W., Zhang, Q., Wu, W., Wang, L., Fan, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059771 · Cited by 99
Kurebayashi, Y., Emoto, K., Hayashi, Y., Kamiyama, I., Ohtsuka, T., Asamura, H., & Sakamoto, M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0214 · Cited by 92
Self-citationLymphoepithelioma-Like Carcinoma in Liver
Labgaa, I., Stueck, A., & Ward, S. C. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.02.022 · Cited by 91
CD169 identifies an anti‐tumour macrophage subpopulation in human hepatocellular carcinoma
Zhang, Y., Li, J., Jiang, Z.-Z., Li, L., Wu, Y., & Zheng, L. (2016) · The Journal of Pathology · doi:10.1002/path.4720 · Cited by 81
Fu, Y., Yi, Y., Cai, X., Sun, J., Ni, X., He, H.-W., Wang, J., Lu, Z., Huang, J., Cao, Y., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.47 · Cited by 73
Mathai, A. M., Kapadia, M. J., Alexander, J., Kernochan, L. E., Swanson, P. E., & Yeh, M. M. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824e9b7c · Cited by 65
Tsujikawa, H., Masugi, Y., Yamazaki, K., Itano, O., Kitagawa, Y., & Sakamoto, M. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.10.014 · Cited by 57
Self-citationLi, J., Yu, X.-J., Wang, Y., Huang, L., Liu, C., Zheng, L., Fang, Y., & Xu, J. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1139-2 · Cited by 54
The immunosuppressive tumor microenvironment in hepatocellular carcinoma
Pang, Y., Zhang, H., Peng, J., Pang, X., Yu, S., Xing, Q. R., Yu, X., Gong, L., Yin, Y., Zhang, Y. X., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0603-5 · Cited by 52
Molecular Diagnosis of Multistage Hepatocarcinogenesis
Sakamoto, M., Effendi, K., & Masugi, Y. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq099 · Cited by 42
Self-citationGETPrime 2.0: gene- and transcript-specific qPCR primers for 13 species including polymorphisms
David, F. P. A., Rougemont, J., & Deplancke, B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw913 · Cited by 32
Cited by
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.10.001 · Cited by 851
Targeted therapy for hepatocellular carcinoma
Huang, A., Yang, X.-R., Chung, W.-Y., Dennison, A. R., & Zhou, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00264-x · Cited by 739
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Molecular and histological correlations in liver cancer
Calderaro, J., Ziol, M., Paradis, V., & Zucman-Rossi, J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.001 · Cited by 590
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K.-W., Guan, X.-Y., & Ma, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 460
Metadata
- Authors
- Kurebayashi, Y., Ojima, H., Tsujikawa, H., Kubota, N., Maehara, J., Abe, Y., Kitago, M., Shinoda, M., Kitagawa, Y., & Sakamoto, M.
- Venue
- Hepatology
- Published
- 2018-07-25
- Volume
- 68
- Issue
- 3
- Pages
- 1025-1041
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2795334950
- Cited by
- 454
- References
- 42
- FWCI
- 14.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.